Bristol Myers Squibb (NYSE: BMY) has announced results from its Phase 3 CheckMate -67T trial, which could revolutionize treatment for patients with advanced or metastatic clear cell renal cell carcinoma (ccRCC). The trial evaluated the subcutaneous formulation of PD-1 immune checkpoint inhibitor Opdivo (nivolumab), co-formulated with Halozyme’s proprietary recombinant human hyaluronidase (rHuPH20), referred to as […]
Merck & Co., Inc., a global healthcare leader, has recently unveiled groundbreaking results from its Phase 3 KEYNOTE-564 trial. This pivotal study demonstrates that KEYTRUDA, Merck’s innovative anti-PD-1 therapy, significantly reduces the risk of death by 38% compared to placebo, marking a milestone in adjuvant therapy for patients with renal cell carcinoma (RCC) post-nephrectomy. Presented […]
Global pharmaceutical leader Merck has announced that WELIREG (belzutifan), its pioneering oral HIF-2α inhibitor, has achieved a critical milestone in its Phase 3 trial LITESPARK-005. The trial, conducted on adult patients with advanced renal cell carcinoma (RCC) that progressed following PD-1/L1 checkpoint inhibitor and VEGF-TKI therapies, met its primary endpoint by demonstrating a statistically significant […]
LG Chem acquisition of Aveo Oncology : South Korea’s LG Chem has entered into a definitive agreement to acquire Aveo Oncology, a US-based biotech company, in an all-cash transaction valued at $566 million. The acquisition of Aveo Oncology is expected to increase the commercial footprint of LG Chem’s life sciences division in the US and […]
The US Food and Drug Administration (FDA) has approved the combination of Bristol Myers Squibb’ Opdivo (nivolumab) and Exelixis’ Cabometyx (cabozantinib) as a first line therapy for advanced renal cell carcinoma (RCC), a type of kidney cancer. As per the FDA approval, Opdivo 240mg has to be injected intravenously every two weeks or 480mg every […]
Merck acquisition of Peloton : Pharma giant Merck is set to acquire US biopharma company Peloton Therapeutics in a deal worth up to $2.2 billion, according to pharma acquisition news. Based in Texas, Peloton Therapeutics is a clinical-stage company engaged in the development of small molecule therapeutics that target hypoxia-inducible factor-2α (HIF-2α) for the treatment […]
